What did @taylor_ranftle actually say?
Taylor said she's injecting BPC-157, NAD+, TB-500, and GHK-Cu daily as a morning routine, describing it as "the wave" she's riding heading into her 32nd birthday. The headline claim is experiential: "never felt better, never felt younger, never looked hotter." No specific benefits are named, no doses are mentioned, and no mechanism is explained. It's pure vibe-based testimony, which makes it both hard to debunk and hard to validate.
To her credit, she doesn't claim to have cured anything. She doesn't tell viewers to do what she's doing. But 36,000 views of someone excitedly describing a multi-peptide injection routine carries real influence, and the absence of caveats is itself a kind of claim. When wellness content makes you feel like you're missing out, that's doing persuasive work even without a single factual statement.
Does the science back this up?
For some of these compounds, there's legitimate early-stage research. For others, the human evidence is thin to nonexistent. The stack as a whole has never been studied in combination, and "never felt younger" is not a measurable outcome in any published trial.
BPC-157 has the most animal data. Sikiric et al. (2018, Current Pharmaceutical Design) documented accelerated tendon and gut healing in rodent models, but peer-reviewed human clinical trials remain scarce. TB-500, a synthetic fragment of thymosin beta-4, shows wound-healing and anti-inflammatory signals in preclinical work, but again, robust human RCTs are missing. GHK-Cu has legitimate cosmetic dermatology literature behind it, including Pickart and Margolina (2018, Symmetry) on collagen synthesis, though most of that is topical, not injectable. NAD+ precursors have the strongest human data of the group: Yoshino et al. (2021, Science) showed metabolic improvements in postmenopausal women with NMN supplementation. But IV or injectable NAD+ is a different delivery question than what the supplement trials studied.
What did they get wrong (or right)?
She got one thing right without knowing it: stacking peptides with complementary mechanisms is at least theoretically coherent. BPC-157 and TB-500 are often discussed together in the recovery literature because their proposed pathways differ enough that redundancy is less of a concern. That's not an endorsement, but it's not random either.
What she got wrong, or at least left dangerously unaddressed, is the regulatory and safety context. These peptides are not FDA-approved for the uses she's implying. BPC-157 and TB-500 are not approved for human therapeutic use in the US. The FDA issued warning letters to compounding pharmacies in 2023 specifically about BPC-157, flagging it as a drug substance that cannot legally be compounded under federal law. Injecting unapproved, unregulated substances carries real risks: contamination, incorrect dosing, unknown long-term effects. Saying "I hate needles but I do it anyway" makes it sound low-stakes. It isn't.
What should you actually know?
The peptide therapy space sits in a regulatory gray zone that is actively shrinking. The FDA's 503A and 503B compounding rules are being tightened, and several peptides that were widely available through compounding pharmacies are now restricted. If you're considering any of these compounds, the sourcing question matters as much as the science question.
The "never felt younger" framing is also worth interrogating. At 32, with no baseline labs shown, no control condition, and no blinding, Taylor's subjective experience tells us something about her placebo response and her enthusiasm, not about what the peptides are doing. That's not a criticism of her. That's just how self-reported wellness works.
- BPC-157: animal data is interesting, human trial data is nearly absent, and FDA compounding restrictions apply as of 2023.
- TB-500: similar preclinical promise, similar human evidence gap, similar regulatory status.
- GHK-Cu: most evidence supports topical use for skin; injectable human data is limited.
- NAD+: strongest human evidence base of the four, but delivery method and dose matter in ways this video doesn't address.
- Multi-peptide stacks: no combined human safety or efficacy data exists in peer-reviewed literature.
If a telehealth provider is recommending this stack without labs, a clinical rationale, and informed consent documentation, that's a problem worth asking about directly.